Zymeworks

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

Retrieved on: 
Monday, April 8, 2024
Prior, CFO, SVP, Zymeworks, News, LLP, Senior, Interim management, Pomerantz, Interim

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Well, Small-cell carcinoma, Therapeutic index, Glomus tumor, Endometrial cancer, Survival, Environment, Service provider, Trichloroethylene, Patient, Primate, Triple-negative breast cancer, Lead, Zymeworks, 3D, Standard of care, Cancer, TAA, Spacecraft, Lung cancer, IND, CD3, DLL3, AACR, Workflow, Antibody, TCE, CD28, Therapy, Stomach, ADC, Vaccine

The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.

Key Points: 
  • The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
  • An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
  • Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)

Retrieved on: 
Tuesday, April 2, 2024
Interim management, Senior, Interim, SVP, Zymeworks, News, CFO, Private investigator

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ).

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ).
  • The investigation concerns whether Zymeworks and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, effective immediately.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

Retrieved on: 
Monday, April 1, 2024
CFO, SVP, Zymeworks, News, LLP, Senior, Interim management, Pomerantz, Interim

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
Therapy, CD28, San Diego Convention Center, Zymeworks, Abstract, Standard of care, Vaccine

Strong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugate

Key Points: 
  • Strong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugate
    VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) --  Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, CA from April 5-10, 2024.
  • “Our team is especially excited to participate in AACR this year to highlight some recent advancements in the development of our next generation antibody-drug conjugate and multispecific antibody therapeutics,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks.
  • “Five abstracts being accepted underscores the strong progress we continue to make in advancing multiple development programs based on our proprietary engineering platforms and integrated technologies.”
    Title: TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve responses in the treatment of solid tumors

Debbie's Dream Foundation: Curing Stomach Cancer Celebrates a Year of Impactful Programs and Community Support in 2023

Retrieved on: 
Wednesday, January 3, 2024
Veteran, Stomach, Travel, Amgen, ASCO, Caregiver, DDF, Daiichi Sankyo, Research, Zymeworks, DSI, Copper, Stomach cancer, Federation, Genetics, BMS, United Way, Mind, Patient, Medicine, Bristol Myers Squibb, Club, Pharmaceutical industry

FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners. The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors. This year, DDF worked closely with sponsors such as Amgen, Arcus, Astellas, Bristol Myers Squibb (BMS), Daiichi Sankyo (DSI), Genentech, Lilly Oncology, Merck, Taiho Oncology, and Zymeworks, whose dedication has been instrumental in advancing various programs, ensuring DDF's continued service to patients, their families, and caregivers.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners.
  • The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors.
  • At the top of the year, DDF hosted its Inaugural Patient Advocate Retreat during its 11th Annual Stomach Cancer Capitol Hill Advocacy Day in Washington, D.C.
  • For the 2023 Symposia series, DDF collaborated with Moffitt Cancer Center in Tampa, Florida, to host a Stomach Cancer Educational Symposium.

Reverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokines 

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Professional Services, Health, Philanthropy, General Health, Pharmaceutical, Oncology, Other Philanthropy, Research, Science, Finance, Amplifier, Multiple myeloma, Cytokine, School, Preamplifier, Alexion, AstraZeneca, Therapy, Toxicity, University of British Columbia, Boehringer Ingelheim, Risk, Flagship Pioneering, CSO, MMRF, Patient, Systems biology, Element, SAB, Amplitude, University, Antibody, Zymeworks, Cancer, Neoplasm, Harvard University, Biomedical engineering, Cell, Immunoglobulin G, Vaccine, Management, Pfizer, Reverberation

Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .

Key Points: 
  • Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .
  • Reverb Therapeutics is advancing its novel antibody-based AmplifierTM platform to treat a broad range of diseases with endogenous cytokines that naturally occur within the body.
  • Instead of using heavily engineered exogenous cytokines to treat disease—which have consistently presented challenges such as systemic toxicity, immunogenicity and challenging production requirements—Reverb’s antibodies redirect endogenous, natural cytokines to cells of interest.
  • “We are keenly aware of the clinical obstacles to more widespread use of exogenous cytokines to treat patients,” said David de Graaf, Ph.D., Co-founder and CEO of Reverb Therapeutics.

Global ADC (Antibody Drug Conjugates) Market Research Report 2023-2035: Focus on ADC Linker and ADC Conjugation Technologies - Over 420 ADCs are Currently Being Evaluated - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Conjugation, USFDA, Biomarker, DAR, Seagen, Research, Engineering, ADC, Neoplasm, Zymeworks, Spacecraft, Partnership, Generation, Overalls, Safety, Toxicity, Fine chemical, Vaccine, Linker, Gemtuzumab ozogamicin

The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during 2023-2035.

Key Points: 
  • The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during 2023-2035.
  • The challenges associated with conventional drug products have led to the development of advanced ADC linker and ADC conjugation technologies.
  • The ADC technologies market landscape features an extensive list of over 65 large, mid-sized and small companies that offer more than 95 ADC linker and conjugation technologies.
  • These platforms include linker technologies, linker-payload technologies and antibody conjugation technologies for the development of ADC.

Zymeworks Announces New Director Nominee

Retrieved on: 
Monday, October 16, 2023
Gene expression, Cancer, Internal medicine, Biology, Breast cancer, AACR, Apoptosis, Society, Cyber Security Collaborative Research Alliance, IND, University of Washington Department of Global Health, Fred Hutchinson Cancer Research Center, University, National Cancer Institute, Wellesley College, Disease, Hormone, Johns Hopkins Hospital, American Association for Cancer Research, Johns Hopkins, Harvard Medical School, Publication, Executive, ASCO, Molecular biology, Woman, Patient, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Pharmaceutical industry, MD, Zymeworks

“With this in mind, we are delighted to invite Dr. Davidson to join our board of directors.

Key Points: 
  • “With this in mind, we are delighted to invite Dr. Davidson to join our board of directors.
  • Her lab studies have paved the way for new clinical trials of drugs that exploit these pathways to kill breast cancer.
  • Prior to joining FHCC, she spent time at the National Cancer Institute, Johns Hopkins in Baltimore and the University of Pittsburgh.
  • Dr. Davidson completed her residency in Internal Medicine at John Hopkins Hospital and a fellowship at the National Cancer Institute.

Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Docetaxel, GEA, Abstract, Partnership, Therapy, Senior, BeiGene, DOR, ESMO, Calendar, Quality of life, GAAP, Research, EDT, PFS, Public expenditure, Congress, Patient, Cancer, Corr, Item, ADC, Spacecraft, BTC, Ovarian cancer, IND, Regulation S-K, Regulation, Sodium-dependent phosphate transport protein 2B, Tislelizumab, Pharmaceutical industry, Medical imaging, Management, Cryptocurrency, Life insurance, Zymeworks, Jazz, The Lancet

“During the second quarter of 2023, we made excellent progress in advancing several of our key planned corporate goals for the year,” said Kenneth Galbraith, Chair, President and Chief Executive Officer of Zymeworks.

Key Points: 
  • “During the second quarter of 2023, we made excellent progress in advancing several of our key planned corporate goals for the year,” said Kenneth Galbraith, Chair, President and Chief Executive Officer of Zymeworks.
  • In partnership with Jazz and BeiGene, multiple abstracts for zanidatamab were presented at the ASCO Annual Meeting in Chicago in June 2023.
  • Financial Results for the Six Months Ended June 30, 2023
    Revenue for the six months ended June 30, 2023 was $42.6 million compared to $7.4 million for the same period of 2022.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.